|
|
Release Date: August 31, 2009; Expiration Date: August 31, 2010
Estimated Time to Complete: 1 hour.
Sponsored by Veritas Institute for Medical Education, Inc.
Supported by educational grants from Bristol-Myers Squibb and Novartis Oncology,
with additional support from MolecularMD.
Statement of Need/Program Overview
The progression of new therapies for patients with chronic myeloid leukemia (CML)
from the bench to bedside has been rapid, in parallel with the swift advances in
molecular biology. The impact of molecular biology on the diagnosis, monitoring,
and treatment strategies for CML has also been substantial. Although community clinicians
have access to a number of CME/CE activities regarding available treatments and
the associated clinical data, a need remains for education regarding the correlation
of molecular response with the well-understood hematologic and cytogenetic response.
Community clinicians need to understand molecular response, its association with
residual disease, how it is measured, and the interpretation and application of
molecular tests.
This On-Demand CME/CE activity will offer physicians, nurses, nurse practitioners,
and physician assistants a series of essential topics in CML within a manageable
time frame. You may earn up to 1.0 AMA PRA Category 1 CreditTM
or 1.0 contact hour by participating in this activity, which comprises 4 modules
highlighting the role of frequent molecular testing in guiding management strategies
for patients with CML. It will assess methodologies used for monitoring response,
evaluate the relationship between cytogenetic/molecular response and disease state,
and outline ways to implement frequent molecular testing utilizing current guidelines
and recommendations.
Target Audience
Hematologists, hematologist/oncologists, medical oncologists, oncology nurses, nurse
practitioners, and physician assistants who treat patients with chronic myeloid
leukemia
Learning Objectives
Module 1:
You will assess the methodologies used for monitoring response and evaluate the
relationship between cytogenetic response, molecular response, and residual disease
in patients with chronic myeloid leukemia (CML).
You will evaluate the prognostic significance of the timing, depth, and stability
of molecular response and be better able to use molecular monitoring results in
guiding management decisions.
Module 2:
You will be able to explain molecular response results in relation to the development
of resistance-conferring mutations and disease progression, validating the role
of frequent molecular testing in guiding management decisions.
In light of updated recommendations and guidelines, you will be able to implement
frequent molecular monitoring into your practice.
Accreditation/Designation of Credit Statements
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing medical education
for physicians.
Physicians
Veritas Institute for Medical Education, Inc. designates this educational
activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation
in the activity.
Nurse Practitioners
Veritas Institute for Medical Education, Inc. approved as a provider
for nurse practitioner continuing education by the American Academy of Nurse Practitioners:
AANP Provider Number 040309. This program has been approved for 1 contact hour
of continuing education (which include 1 hour of pharmacology).
Nurses
Veritas Institute for Medical Education, Inc. approved by the California Board of
Registered Nursing, Provider #13986 for 1.0 Contact Hour.
Method of Participation
- Complete both Modules—1 and 2—to receive credit
- Complete the CME/CE Activity Evaluation and Request for Credit Form
- Print your CME certificate or nursing statement of completion.
These activities are provided free of charge to participants.
Faculty
Click on the name of a faculty member to view full bio, and click once more to close
bio.
|
|
Chair
|
Nurse Contributor
|
|
|
|
|
Associate Professor, Medicine and Oncology
|
Research Nurse Manager, Leukemia
|
|
University of Washington
|
University of Texas M.D. Anderson
|
|
Clinical Research Division
|
Cancer Center
|
|
Fred Hutchinson Cancer Research Center
|
Houston, Texas
|
|
Seattle, Washington
|
|
|
Financial Disclosure Statement
In accordance with the ACCME’s Standards for Commercial Support, all CME providers
are required to disclose to the activity audience the relevant financial relationships
of the planners, teachers, and authors involved in the development of CME content.
An individual has a relevant financial relationship if he or she has a financial
relationship in any amount occurring in the last 12 months with a commercial interest
whose products or services are discussed in the CME activity content over which
the individual has control. Disclosures are as follows:
Jerald P. Radich, MD: Bristol-Myers Squibb; Novartis Oncology (grant/research
support, consultant).
Mary Beth Rios, RN: Advanced Health Media (speakers bureau); Gardiner Caldwell
(consultant).
The staff of Veritas Institute for Medical Education, Inc. has nothing to disclose.
Off-Label/Investigational Uses of Drugs/Medical Devices Disclosure
Participants are advised that this CME/CE activity will contain references to unlabeled/unapproved/investigational
uses of drugs to treat patients with CML.
Disclaimer
The opinions expressed in this activity are those of the presenters and do not necessarily
reflect those of Veritas Institute for Medical Education, Inc., Bristol-Myers Squibb,
Novartis Oncology, or MolecularMD. Please consult the appropriate package insert
for full prescribing information on all drug therapies discussed.
|